DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+8.61%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.11B
AUM Growth
+$3.11B
(+0.72%)
Cap. Flow
-$150M
Cap. Flow
% of AUM
-4.82%
Top 10 Holdings %
Top 10 Hldgs %
52.57%
Holding
75
New
6
Increased
18
Reduced
21
Closed
10
Top Buys
| 1 |
Insmed
INSM
|
$150M |
| 2 |
Axsome Therapeutics
AXSM
|
$83.7M |
| 3 |
Vaxcyte
PCVX
|
$45.5M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$34.6M |
| 5 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$25.1M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$264M |
| 2 |
BridgeBio Pharma
BBIO
|
$82M |
| 3 |
Guardant Health
GH
|
$62.1M |
| 4 |
RAPT Therapeutics
RAPT
|
$42.1M |
| 5 |
Amgen
AMGN
|
$35.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
BridgeBio Pharma
BBIO
$9.89B
| $38.9M | 1.25% |
900,000
-1,900,000
| -68% | -$82M |
|
|
AUTL
27
Autolus Therapeutics
AUTL
$399M
| $38.4M | 1.23% |
16,852,147
-997,335
| -6% | -$2.27M |
|
|
MTSR
28
Metsera, Inc. Common Stock
MTSR
$3.71B
| $31.1M | 1% |
1,094,408
| – | – |
|
29
Terns Pharmaceuticals
TERN
$609M
| $28M | 0.9% |
7,495,000
+1,918,442
| +34% | +$7.16M |
|
|
TECX
30
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $27.9M | 0.89% |
1,401,938
| – | – |
|
|
ABVX
31
Abivax
ABVX
$6.12B
| $26.6M | 0.85% |
3,480,144
-99,065
| -3% | -$758K |
|
|
JBIO
32
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $25.1M | 0.8% |
+2,509,301
| New | +$25.1M |
|
|
MBX
33
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $25M | 0.8% |
2,188,592
-830,343
| -28% | -$9.47M |
|
|
CMPS
34
Compass Pathways
CMPS
$424M
| $24.7M | 0.79% |
8,831,007
-28,641
| -0.3% | -$80.2K |
|
35
GH Research
GHRS
$837M
| $24.4M | 0.78% |
2,000,000
| – | – |
|
|
BCAX
36
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $22.5M | 0.72% |
2,426,657
+426,657
| +21% | +$3.96M |
|
|
ORKA
37
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $21.5M | 0.69% |
1,918,798
+474,089
| +33% | +$5.31M |
|
38
enGene Holdings
ENGN
$236M
| $16.6M | 0.53% |
4,557,575
| – | – |
|
39
MindMed
MNMD
$676M
| $16.2M | 0.52% |
2,500,000
| – | – |
|
|
UPB
40
Upstream Bio, Inc. Common Stock
UPB
$923M
| $15.8M | 0.51% |
1,442,767
-856,800
| -37% | -$9.41M |
|
41
Olema Pharmaceuticals
OLMA
$375M
| $14.7M | 0.47% |
3,442,833
| – | – |
|
42
Merus
MRUS
$4.98B
| $14.5M | 0.46% |
+275,000
| New | +$14.5M |
|
|
CYBN
43
Cybin
CYBN
$176M
| $12.8M | 0.41% |
1,529,987
| – | – |
|
44
Cidara Therapeutics
CDTX
$1.66B
| $12.2M | 0.39% |
+250,000
| New | +$12.2M |
|
|
BCYC
45
Bicycle Therapeutics
BCYC
$511M
| $8.36M | 0.27% |
1,203,244
+436,228
| +57% | +$3.03M |
|
|
CBIO
46
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $7.32M | 0.23% |
+453,686
| New | +$7.32M |
|
|
CNTA
47
Centessa Pharmaceuticals
CNTA
$2.25B
| $6.57M | 0.21% |
+500,000
| New | +$6.57M |
|
48
Novavax
NVAX
$1.21B
| $6.29M | 0.2% |
998,542
-519,640
| -34% | -$3.27M |
|
49
Invivyd
IVVD
$204M
| $6.14M | 0.2% |
8,585,980
-1,136,274
| -12% | -$812K |
|
|
50
RAPT Therapeutics
RAPT
$188M
| $6.01M | 0.19% |
751,422
-5,259,958
| -88% | -$42.1M |
|